On March 4, 2019 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, reported a late-breaking poster presentation for its AUTO1 program at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2019 to be held March 29 to April 3 in Atlanta, Georgia (Press release, Autolus, MAR 4, 2019, View Source [SID1234550831]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster presentation details are as follows. The full text of the abstract will be posted to the AACR (Free AACR Whitepaper) website on March 29.

Abstract Number: CT105
Session Name: PO.CT04 – Phase I-III Trials in Progress: Part 1
TITLE: AUTO1, a novel fast off CD19CAR delivers durable remissions and prolonged CAR T cell persistence with low CRS or neurotoxicity in adult ALL
Session Date: Monday, April 1, 2019
Session Time: 1:00 PM – 5:00 PM
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 17

About AUTO1
AUTO1 is a CD19 CAR T cell investigational therapy designed to overcome the limitations in safety – while maintaining similar levels of efficacy – compared to current CD19 CAR T cell therapies. Designed to have a fast target binding off-rate to minimize excessive activation of the programmed T cells, AUTO1 may reduce toxicity and be less prone to T cell exhaustion, which could enhance persistence and improve the T cells’ abilities to engage in serial killing of target cancer cells. In 2018, Autolus signed a license agreement under which Autolus acquired global rights from UCL Business plc (UCLB), the technology-transfer company of UCL, to develop and commercialize AUTO1 for the treatment of B cell malignancies. AUTO1 is currently being evaluated in two Phase 1 studies, one in paediatric ALL and one in adult ALL.
For information about the trials, visit View Source and View Source

On March 4, 2019 Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, reported that it will participate in two upcoming investor conferences (Press release, Halozyme, MAR 4, 2019, View Source [SID1234533920]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 39th Annual Cowen Healthcare Conference on Monday, March 11 at 4:50 p.m. ET / 1:50 p.m. PT in Boston, MA. Dr. Helen Torley, president and chief executive officer, will present an overview of the company.
The Barclays Global Healthcare Conference on Tuesday, March 12 at 3:50 p.m. ET / 12:50 p.m. PT in Miami, FL. Laurie Stelzer, senior vice president and chief financial officer, will present a brief overview of the company followed by a question and answer session.
A live webcast of each presentation can be accessed through the "Investors" section of www.halozyme.com, and a recording will be made available for 90 days following each event. To access a live webcast, please visit Halozyme’s website approximately 15 minutes prior to the presentation to register and download any necessary audio software.

On March 4, 2019 Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, reported that the company’s Chief Executive Officer, Rob Neville, will present at the 39th Annual Cowen and Company Healthcare Conference on Monday, March 11, 2019 at 2:10 p.m. Eastern Time in Salon B of the Boston Marriott Copley Place in Boston (Press release, Savara, MAY 4, 2019, View Source [SID1234533936]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties can access a live audio webcast on the Investors page of the Savara website at www.savarapharma.com/investors/events/. Please connect to the company’s website at least 15 minutes prior to the start of the presentation to ensure sufficient time for any software download that may be required for the webcast. An archived presentation will be available on Savara’s website for 30 days.

On March 4, 2019 MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX & MDAX; Nasdaq: MOR) reported that it will publish its Annual Financial Results 2018 on March 13, 2019 at 10:00pm CET (9:00pm GMT; 5:00pm EDT) (Press release, MorphoSys, MAR 4, 2019, View Source [SID1234533921]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Management team of MorphoSys AG will host a conference call and webcast on March 14, 2019 at 2:00pm CET (1:00pm GMT; 9:00am EDT) to present MorphoSys’s Annual Financial Results 2018 and provide an outlook for 2019.

Date of the conference call: Thursday, March 14, 2019
Time: 2:00pm CET (1:00pm GMT, 9:00am EDT)
Dial-in numbers (listen only)
Germany: +49 69 201 744 220
United Kingdom: +44 203 009 2470
USA: +1 877 423 0830
Participant PIN: 88207738#

Company participants in the call will be:

Dr. Simon Moroney, Chief Executive Officer
Jens Holstein, Chief Financial Officer
Dr. Malte Peters, Chief Development Officer
Dr. Markus Enzelberger, Chief Scientific Officer

Participants are kindly requested to dial in up to 10 minutes before the call to ensure a secure line and a prompt start.

The presentation slides and webcast link will be available at the Company’s website at View Source

A replay of the conference will also be available at the corporate website following the live event.

On March 4, 2019 SpringWorks Therapeutics, a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, reported that Saqib Islam, Chief Executive Officer, will present at the Cowen and Company 39th Annual Health Care Conference in Boston on Tuesday, March 12, 2019, at 3:30 p.m. Eastern Standard Time (Press release, SpringWorks Therapeutics, MAR 4, 2019, View Source [SID1234533937]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!